Clinical Trial of Approaches to Prostate Cancer Surgery (NCT05155501)
Clinical TrIAL of Approaches to Prostate cAncer suRgery
🩺 Plain-English Summary (8th-Grade Level)
This is a prospective, randomized controlled trial to compare cancer control and health-related quality of life following pelvic fascia-sparing radical prostatectomy versus standard radical prostatectomy. The investigators hypothesize that pelvic fascia-sparing radical prostatectomy will have similar cancer control (primary outcome) and sexual function outcomes; and significantly better urinary function, penile shortening/deformity and inguinal hernia risks as compared to radical prostatectomy.
Who can join: Review the eligibility criteria below.
Location: Beckman Research Institute of City of Hope — Duarte, California
Age range: 40 Years to 80 Years
🧪 Interventions in This Study
- Robot-assisted radical prostatectomy (RP) (PROCEDURE)
- Pelvic fascia-sparing robot-assisted radical prostatectomy (PFS-RP) (PROCEDURE)
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (9 Sites)
- Beckman Research Institute of City of Hope — Duarte, California
- Georgetown University — Washington D.C., District of Columbia
- Northwestern University — Chicago, Illinois
- Johns Hopkins University — Baltimore, Maryland
- Beth Israel Deaconess Medical Center (BIDMC) — Boston, Massachusetts
- Hackensack Meridian Health — Hackensack, New Jersey
- NewYork-Presbyterian Queens — Flushing, New York
- Memorial Sloan Kettering Cancer Center — New York, New York
- Weill Cornell Medicine — New York, New York
📞 Contact the Study Coordinator
Phone: (732) 757-2448
Email: mat7051@med.cornell.edu
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Prostate Cancer
- A Study of Apalutamide (JNJ-56021927, ARN-509) Plus Androgen Deprivation Therapy (ADT) Versus ADT in Participants With mHSPC — Homewood, Alabama
- A Study in Which Non-metastatic Castration-resistant Prostate Cancer (nmCRPC) Patients for Whom a Decision to Treat With Darolutamide Has Been Made Before Enrollment Are Observed and Certain Outcomes Are Described — Homewood, Alabama
- Stereotactic Ablative Radiation Therapy for Prostate Cancer — Charleston, South Carolina
- A Study of Stereotactic Body Radiation Therapy (SBRT) Without Androgen Deprivation Therapy (ADT) in People With Unfavorable Intermediate-Risk Prostate Cancer — Basking Ridge, New Jersey
- A Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib (LY2835219) in Participants With Prostate Cancer — Phoenix, Arizona
- Neoadjuvant Enoblituzumab (MGA271) in Men With Localized Intermediate and High-Risk Prostate Cancer — Baltimore, Maryland
Explore by condition: All Prostate Cancer clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.